Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals (AMLX) is a clinical-stage biopharmaceutical company pioneering research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). This page serves as the definitive source for official updates and analysis on the company's therapeutic developments, regulatory milestones, and strategic initiatives.
Investors and researchers will find timely, verified information about clinical trial results, regulatory submissions, and research partnerships. Our curated news collection provides context for understanding Amylyx's progress in developing novel therapies while maintaining compliance with financial disclosure standards.
Key content categories include updates on ALS treatment research, FDA communications, scientific publications, and intellectual property developments. All materials are sourced directly from company filings and verified industry channels to ensure accuracy.
Bookmark this page for streamlined access to essential updates about Amylyx's innovative pipeline and its evolving role in neurodegenerative disease research. Check regularly for new developments in this dynamic clinical-stage biopharma segment.
Amylyx Pharmaceuticals reported full-year 2022 product revenue of $22.2 million, primarily from the launches of RELYVRIO® in the U.S. and ALBRIOZA™ in Canada. In Q4 2022, net product revenue was $21.9 million, while the net loss for the quarter increased to $42.7 million or $0.65 per share. The company announced the appointment of Karen Firestone to its Board of Directors and emphasized upcoming regulatory reviews in the EU. Despite strong launch engagement and ongoing Phase 3 trials, the company is aware of the challenges that lie ahead in expanding access for ALS patients.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced participation in two upcoming virtual investor conferences. Co-CEOs Joshua Cohen and Justin Klee will engage in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 8:40 am ET, followed by a presentation at the Stifel 2023 CNS Days on March 28, 2023, at 11:00 am ET. Both events will be accessible via live webcast on the company's investor relations page.
Amylyx focuses on developing innovative treatments for neurodegenerative diseases and is headquartered in Cambridge, Massachusetts, with operations in Canada and EMEA.
Amylyx Pharmaceuticals will release its fourth quarter and full year 2022 financial results on March 13, 2023, after U.S. market close. Senior management will host a conference call at 4:30 p.m. ET to discuss these results along with other company updates. Investors can access the call by dialing (833) 816-1395 in the U.S. or +1 (412) 317-0488 internationally, and a live audio webcast will be available in the Investor section of the company's website. The event will also be archived for 90 days.
Amylyx is focused on developing innovative treatments for the neurodegenerative disease community.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced that Co-CEOs Joshua Cohen and Justin Klee will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00am ET. The conference will be held virtually, and a live webcast of their presentation will be available in the 'Events' section of the company's website. A replay will be accessible for 90 days post-event. Amylyx is focused on developing innovative treatments for neurodegenerative diseases, with operations based in Cambridge, Massachusetts, and across Canada and EMEA.
Amylyx Pharmaceuticals has completed enrollment for the Phase 3 clinical trial, PHOENIX, evaluating AMX0035 for treating amyotrophic lateral sclerosis (ALS). This global, placebo-controlled study enrolled 664 participants and aims to assess the treatment's safety and efficacy over 48 weeks. Topline results are expected in 2024. The trial builds on positive outcomes from the prior Phase 2 CENTAUR trial, which demonstrated significant functional benefits and potential survival advantages. The European Medicines Agency is currently reviewing the marketing application for AMX0035, with a decision anticipated in early 2023.
Amylyx Pharmaceuticals (NASDAQ: AMLX) will have Co-CEOs Joshua Cohen and Justin Klee participate in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 3:05 p.m. ET. The conference will take place virtually, and a live webcast can be accessed on the company's investor relations website. A replay will be available for 90 days post-event. Amylyx Pharmaceuticals is dedicated to innovating treatments for the neurodegenerative community and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals (AMLX) announced significant updates, including the FDA approval and commercial launch of RELYVRIO™ for ALS treatment in the U.S. and the ongoing launch of ALBRIOZA™ in Canada. For Q3 2022, net product revenue reached $0.3 million, primarily from ALBRIOZA sales. Research and development expenses surged to $24.9 million, and general expenses rose to $29.9 million. The net loss was $53.8 million, or $0.92 per share. Cash reserves stood at $162.6 million after an upsized public offering raised $230.8 million.
Amylyx Pharmaceuticals will announce its third quarter 2022 financial results on November 10, 2022, after U.S. market close. The management team will hold a conference call at 4:30 p.m. ET to discuss the results and company updates. Investors can access the call by dialing either (877) 870-4263 for local or (412) 317-0790 for international attendees. A live audio webcast will also be available on the company's investor website, with an archive accessible for 90 days.
Amylyx Pharmaceuticals announced the successful completion of its upsized public offering, raising $246.3 million through the sale of 7,697,812 shares at $32.00 each. The offering included the full exercise of an option for an additional 1,004,062 shares. The funds generated will support the company's efforts in developing innovative treatments for the neurodegenerative community. The offering was managed by a consortium of financial firms, including Goldman Sachs and BofA Securities.
Amylyx Pharmaceuticals has announced an upsized public offering of 6,693,750 shares of common stock, priced at $32.00 per share, expected to generate gross proceeds of $214.2 million. The offering is set to close around October 11, 2022, pending customary conditions. The company has granted underwriters a 30-day option for an additional 1,004,062 shares. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are the joint book-running managers of the offering. Registration statements became effective on October 6, 2022.
FAQ
What is the current stock price of Amylyx Pharmaceuticals (AMLX)?
What is the market cap of Amylyx Pharmaceuticals (AMLX)?
